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The p53 tumor suppressor can restrict malignant
transformation by triggering cell-autonomous pro-
grams of cell-cycle arrest or apoptosis. p53 also
promotes cellular senescence, a tumor-suppressive
program that involves stable cell-cycle arrest and
secretion of factors that modify the tissue microenvi-
ronment. In the presence of chronic liver damage, we
show that ablation of a p53-dependent senescence
program in hepatic stellate cells increases liver
fibrosis and cirrhosis associated with reduced
survival and enhances the transformation of adja-
cent epithelial cells into hepatocellular carcinoma.
p53-expressing senescent stellate cells release fac-
tors that skew macrophage polarization toward a
tumor-inhibiting M1-state capable of attacking se-
nescent cells in culture, whereas proliferating p53-
deficient stellate cells secrete factors that stimulate
polarization of macrophages into a tumor-promoting
M2-state and enhance the proliferation of prema-
lignant cells. Hence, p53 can act non-cell autono-
mously to suppress tumorigenesis by promoting
an antitumor microenvironment, in part, through
secreted factors that modulate macrophage
function.INTRODUCTION
The p53 tumor suppressor acts as a central node in cellular
stress response programs induced by DNA damage and onco-
gene activation (Vousden and Prives, 2009). p53 binds DNA in
a sequence-specific manner and controls the expression of
target genes that mediate its diverse effects (Vousden and
Prives, 2009). p53 can limit the propagation of premalignant cells
by promoting cell-cycle exit or apoptosis, though p53 has
other functions that contribute to its tumor-suppressive action
depending on context (Li et al., 2012). Consequently, p53muta-
tions enable the unrestrained proliferation of damaged cells and
thereby promote tumorigenesis in many tissue types.Cellular senescence is another p53-dependent program that
limits tumorigenesis (Collado and Serrano, 2010). Senescence
is a form of proliferative arrest that is associated with the stable
repression of E2F target genes. However, senescent cells also
downregulate the production of extracellular matrix (ECM) pro-
teins, upregulate ECM-degrading enzymes, and secrete a vari-
ety of immune modulators and inflammatory cytokines (Coppe´
et al., 2008), an effect that is mediated by cooperation between
p53 and nuclear factor-kB (NF-kB) (Chien et al., 2011; Jing et al.,
2011). Collectively, these properties define the senescence-
associated secretory phenotype (SASP) and are associated
with marked changes in protein secretion (Campisi and d’Adda
di Fagagna, 2007).
SASP factors can reinforce the senescence program and influ-
ence tissuemicroenvironment. Thus, key SASP factors can act in
an autocrine manner to reinforce senescent growth arrest
(Acosta et al., 2008; Kuilman et al., 2008) and/or provoke immune
surveillance of the senescent cells, leading to their elimination
(Kang et al., 2011; Krizhanovsky et al., 2008; Reimann et al.,
2010; Xue et al., 2007). In the context of certain wound-healing
responses, SASP limits the extent of tissue damage and facili-
tates wound resolution (Kong et al., 2012; Krizhanovsky et al.,
2008). However, the impact of SASP on malignant initiation or
progression is poorly understood, with studies suggesting that
the program can be either pro- or antitumorigenic (Coppe´ et al.,
2008; Kang et al., 2011; Krtolica et al., 2001; Xue et al., 2007).
We explore the biology of a stromal-derived SASP program
triggered by p53 on cancer initiation in the liver, a well-studied
setting in which the microenvironment strongly influences
epithelial tumorigenesis (Zhang and Friedman, 2012). In this
tissue, tumor initiation is often preceded by hepatic fibrosis re-
sulting from liver damage produced by chronic hepatitis, alcohol,
or chemical insults. Here, dying hepatocytes trigger the prolifer-
ation of hepatic stellate cells (HSCs), which accumulate in the
liver and coordinate the production of ECM components that
form the fibrotic scar. During chronic injury, an ongoing cycle
of cell death, HSC proliferation, inflammation, and fibrosis even-
tually leads to organ failure through cirrhosis, which is the stron-
gest risk factor for the emergence of hepatocellular carcinoma
(HCC)—the third leading cause of cancer deaths worldwide
(Bataller and Brenner, 2005).
We previously implicated a p53-dependent senescence
program as part of a tissue homeostatic mechanism thatCell 153, 449–460, April 11, 2013 ª2013 Elsevier Inc. 449
Figure 1. p53 Action in HSCs Limits Fibrosis
(A) Transgenic mice were treated with CCl4 for 6 weeks, and fibrosis was as-
sessed by Sirius red (top) and H&E (bottom) staining. Scale bars, 100 mm.
(B) Quantification of fibrosis based on Sirius red staining by laser scanning
cytometry. At least three liver sections were analyzed per mouse (number of
mice: n = 12, GFAP-Cre; n = 14, p53-LoxP; n = 20, HSC-p53D/D). Values are
mean + SD.
(C andD) Immunoblot showing expression of aSMA in the livers ofmice treated
with CCl4 for 6 weeks (C). Quantification of aSMA relative to b-actin levels
using ImageJ software (D). Values are mean + SD.
H&E, hematoxylin and eosin; aSMA, a-smooth muscle actin.
See also Figure S1.restricts the extent of fibrosis and facilitates its resolution
(Krizhanovsky et al., 2008). Specifically, we observed that, after
an initial proliferative phase associated with fibrogenesis,
HSCs eventually senesce. We demonstrated that this p53-
mediated senescence program limits the extent of fibrosis by
halting HSC proliferation through the cell-autonomous action
of canonical senescence regulators and the non-cell-autono-
mous effects of SASP on ECMand immune surveillance. Consis-
tent with this model, mice in which p53 was disabled specifically
in HSCs displayed excessive fibrosis following chronic fibro-
genic treatment. Here, we evaluate how p53 activity in HSCs
influences later stages of liver disease and, ultimately, epithelial
cancer development. Our results imply that p53 action can
restrict cancer through non-cell-autonomous mechanisms
and underscore the interplay between p53 and the tissue
microenvironment.
RESULTS
p53 Action in HSCs Limits Fibrosis
To investigate the impact of p53 activity in HSCs during different
stages of liver damage, we conditionally deleted p53 expression
in murine HSCs. Transgenic mice expressing Cre recombinase
from the glial fibrillary acidic protein (GFAP) promoter (which, in
the liver, is specifically expressed in HSCs) were crossed with
mice harboring LoxP sites in introns 1 and 10 of the p53 gene
(p53LoxP/LoxP) (Marino et al., 2000). Although the GFAP promoter
is primarily expressed in the adult astroglia, GFAP-Cre;
p53LoxP/LoxP conditional knockout mice show no increased evi-
dence of brain tumors or any other disease (Marino et al.,
2000), thus allowing us dissect the role of p53 in HSCs
without other confounding phenotypes. Hereafter, GFAP-Cre;
p53LoxP/LoxP conditional knockout mice are designated as
HSC-p53D/D, whereas single-transgenic control strains are
referred to as GFAP-Cre or p53-LoxP.
We subjected 8-week-old mice to a 6 week treatment with
carbon tetrachloride (CCl4), a well-studied fibrosis-inducing
agent (Oakley et al., 2005). Of note, cellular responses to liver
damage are highly sex dependent (Naugler et al., 2007), so in
most of our analyses, only females were used for comparison.
Upon liver damage, HSCs become ‘‘activated’’—i.e., they
differentiate into myofibroblasts, proliferate, and produce the
ECM network that constitutes the fibrotic scar (Bataller and
Brenner, 2005). As expected, the protocol produced liver
fibrosis as assessed by staining with Sirius red, which directly
marks the collagen within the ECM, and with hematoxylin and
eosin staining (H&E), which is used to evaluate the overall liver
morphology (Figure 1A). As quantified by laser scanning
cytometry, 3% of the liver was Sirius-red positive in treated
HSC-p53D/D mice, representing an 50% increase over con-
trols (Figure 1B). Similar results were observed when animals
were treated with DDC (3,5-diethoxycarbonyl-1,4-dihydrocolli-
dine), a different fibrogenic compound (Figures S1A–S1C
available online), though accurate quantification was
confounded owing to the appearance of red precipitates in
the liver. Livers from HSC-p53D/D transgenic mice treated
with CCl4 also showed an expansion of activated HSCs as
determined by immunoblotting of a-smooth muscle actin450 Cell 153, 449–460, April 11, 2013 ª2013 Elsevier Inc.(aSMA) in tissue extracts (Figures 1C and 1D) and increased
production of collagen (data not shown). The above findings
are consistent with those using the same protocol in which
p53 was ablated in the whole animal or selectively downregu-
lated in HSCs using transgenic RNAi (Krizhanovsky et al.,
2008), confirming a role for HSC-expressed p53 in limiting
fibrosis.
p53 Activity in HSCs Restrains Cirrhosis
The excessive ECMproduced byHSCs during chronic liver dam-
age disrupts liver architecture, preceding frank cirrhosis and
eventual liver failure. Cirrhosis is associated with a grossly dis-
rupted liver architecture and parenchymal destruction and can
be accompanied by the aberrant retention of fluids in the abdom-
inal cavity (ascites), as well as pathognomonic serum levels of
proteins and enzymes produced by the liver (Bataller and
Figure 2. p53 Activity in HSCs Restrains
Cirrhosis
(A) Abdomen width and mouse weight (week 8)
and ALT and albumin levels (week 13) in mice
treated with CCl4. Values are mean + SD, n = 4,
GFAP-Cre; n = 5, p53-LoxP; n = 3, HSC-p53D/D.
(B) Ultrasound imaging of transgenic mice treated
with CCl4 (week 8 of treatment). The live whole-
mouse images show ascites only in representative
HSC-p53D/D male mice.
(C) Kaplan-Meier curve documenting survival of
mice treated with CCl4. Arrowhead indicates
beginning of CCl4 treatment. Statistical compari-
son of Kaplan-Meier curves is based on the log
rank test. Representative livers are displayed
(white arrows represent liver retraction). Scale
bars, 1 cm. GFAP-Cre in gray, n = 14; p53-LoxP in
green, n = 20; HSC-p53D/D in black, n = 19.
(D) HSC-p53D/D, but not single-transgenic (GFAP-
Cre and p53-LoxP), mice treated with CCl4 ex-
hibited disrupted liver histology evaluated by H&E
staining. Scale bars, 100 mm.
W8, week 8; abd, abdomen width; n, number of
mice; ALT, alanine transaminase; H&E, hematox-
ylin and eosin.
See also Figure S2.Brenner, 2005). To study HSC-specific functions of p53 in more
advanced stages of liver damage, we challenged male and fe-
male mice by treating them twice a week with CCl4, a chronic
regimen known to produce cirrhosis after 12 weeks of treatment
(Oakley et al., 2005). By 13 weeks, most of CCl4-treated HSC-
p53D/D females displayed signs of overt ascites (Figure 2A), as
well as abdominal distension and weight gain when compared
to similarly treated controls (Figure 2A). Accordingly, liver dam-
age in HSC-p53D/D mice was more pronounced, as indicated
by decreased serum albumin and increased alanine transami-
nase levels measured after 13 weeks of treatment (Figure 2A).
These pathological changes were obvious much earlier in male
mice, which are more susceptible to liver damage (Naugler
et al., 2007). In fact, in HSC-p53D/D males, retraction of the liver
was identified by ultrasound examination as early as week 8 of
treatment (Figure 2B).
The excessive liver damage occurring in HSC-p53D/D mice
was associated with increased mortality. Although a few sin-
gle-transgenic females exposed to CCl4 diedwithin 90 days (Fig-
ure 2C), the vastmajority survived beyond 200 days. By contrast,
most HSC-p53D/D mice died within the first 90 days of CCl4
exposure (Figure 2C). Histological examination of HSC-p53D/D
livers revealed a disrupted cytoarchitecture when compared to
single-transgenic controls (Figure 2D). HSC-p53D/D mice
showed more extensive fibrosis, pointing to liver failure as
the likely cause of death. Together, these results indicate thatCell 153, 449–4p53 activity in HSCs acts to protect organ
function following liver damage.
Further characterization of liver pathol-
ogy in moribund HSC-p53D/D mice re-
vealed the presence of small tumors
rarely seen in controls (Figures S2A andS2B; p = 0.029 and p = 0.017, relative to GFAP-Cre and p53-
LoxP, respectively). Histological analyses could not determine
the precise origin of these tumors, and their enrichment on the
liver surface suggested that they might have infiltrated from an
extrahepatic site (Figure S2A). To determine whether these tu-
mors may have been triggered by aberrant Cre-activation and
p53 recombination, we performed PCR analysis of tumor DNA
to assess the status of the conditional p53 allele. Interestingly,
60% of the tumors retained intact p53 genes (Figures S2C and
S2D). Thus, p53 deletion in HSCs appeared to create a liver envi-
ronment that promotes tumorigenesis.
p53 Activity in HSCs Limits Epithelial Tumorigenesis
The above results prompted us to study how HSC-expressed
p53 influences liver tumor development. To specifically produce
tumors in the epithelial compartment, we modified our approach
by combining CCl4 fibrogenic treatment with coadministration of
the carcinogen diethylnitrosamine (DEN) (Figure 3A). This carcin-
ogen generates tumors in mice resembling aggressive HCC as
assessed histopathologically and by gene expression profiling
(Lee et al., 2004). To rule out the possibility that aberrant Cre
activation (and hence p53 gene deletion) contributes to tumor
formation in these cells, we used the compound transgenic
HSC-p53D/D;Rosa26-LSL-LacZ, which allowed us to trace cells
in which GFAP-Cre allele was active by conventional b-galacto-
sidase (b-gal) staining. The resulting mice were treated with the60, April 11, 2013 ª2013 Elsevier Inc. 451
Figure 3. p53 Activity in HSCs Limits Epithe-
lial Tumorigenesis
(A) Schematic diagram indicating the time points
for DEN and CCl4 treatment.
(B and C) Number of macroscopic tumors.
Scatterplot representation: dots indicate individ-
ual animals and bars mean ± SD. If the top
and bottom values are deleted in all groups:
p = 0.0119 (GFAP-Cre versus HSC-p53D/D) and
p = 0.0039 (p53-LoxP versus HSC-p53D/D). If
the outlier in HSC-p53D/D mice is removed:
p = 0.0640 (GFAP-Cre versus HSC-p53D/D) and
p = 0.0318 (p53-LoxP versus HSC-p53D/D).
Representative livers from the three genotypes
are displayed. Scale bars, 1 cm. Black arrows
indicate tumors.
(D) H&E (top) and reticulin (bottom) staining of a
representative liver from treated HSC-p53D/D
mice. Right, magnification of the boxed area on
the left. Scale bars, 100 mm.
(E) Liver tissues (H&E staining, left) were stained
for transgenic Lac-Z expression (b-gal staining).
b-gal positive HSCs accumulated in the fibrotic
scars (top). However, liver tumor cells were b-gal
negative, indicating absence of recombination
events. HSC-p53D/D;R26-LSL-Lacz triple-trans-
genic mice were used, and 36 livers were
analyzed.
W, weeks; D, days; H&E, hematoxylin and eosin;
T, tumor; A, adjacent liver; b-gal, b-galactosidase.
See also Figure S3.regimen shown in Figure 3A, with DEN being administered
15 days after birth and CCl4 provided for 12 weeks, starting
42 days later. Animals were sacrificed 2 days after the last
CCl4 injection (day 142), and their livers were examined for tumor
incidence and histology.
Despite the initiation of the fibrogenic treatment several weeks
after administration of the carcinogen, HSC-p53D/D livers
showed nearly 2-fold more tumors when compared to controls
(Figures 3B and 3C; p = 0.022 and p = 0.015, relative to452 Cell 153, 449–460, April 11, 2013 ª2013 Elsevier Inc.GFAP-Cre and p53-LoxP). All of the
analyzed tumors were of epithelial origin
with an HCC histology, showing typical
reticulin loss within the tumor nodules
(n = 147; Figures 3D and S3A). These
tumors were not b-gal positive (n = 36
tumors analyzed from seven HSC-
p53D/D;Rosa26-LSL-LacZ mice; Fig-
ure 3E) and showed no evidence of p53
gene deletion (Figure S3B). By contrast,
b-gal expression was observed in fibrotic
regions of the treated livers consistent
with efficient Cre-mediated recombina-
tion in the HSC compartment. Although
the incidence of tumors was increased
in HSC-p53D/D mice, overall size and
grade were similar to the control geno-
types (data not shown). These observa-
tions imply that p53 action in HSCs canreduce HCC initiation, thereby restricting tumorigenesis in a
non-cell-autonomous manner.
p53 Regulates SASP of HSCs and Genes Affecting
Macrophage Function
The ability of p53 to act non-cell autonomously to suppress
tumorigenesis suggests that it engages a program that influ-
ences tissue microenvironment, perhaps via its action on senes-
cence and SASP. As a first step toward understanding
Figure 4. p53 Regulates SASP of HSCs and
Genes Affecting Macrophage Function
(A) Activated HSCs from CMV-rtTA;TG-p53.
1224 mouse in the presence or absence of
Dox (proliferating or senescent, respectively) by
phase-contrast microscopy for changes in
morphology (top) and expression of GFP
(bottom).
(B) Activation of p53 was sufficient to restrict
colony formation as assessed by crystal violet
staining 10 days after plating.
(C) GSEA plot evaluating changes in p53
pathway (KEGG_p53) depending on p53
expression.
(D) GO analysis of genes significantly down-
regulated (red) or upregulated (blue) upon p53
expression. Differentially expressed genes were
identified by comparing senescent (blue) versus
proliferating (red) HSCs. Representative exam-
ples are displayed.
(E and F) Murine cytokine array for conditioned
media from proliferating versus senescent HSCs.
Bars represent the average of intensity of two
independent experiments (log2). Factors showing 2-fold increase (blue) or decrease (red) on senescent versus proliferating HSCs are shown. In the right,
representative blots from the cytokine array (F).
ES, enrichment score; NES, normalized enrichment score; S, senescent; P, proliferating.
See also Figure S4 and Table S1.mechanism, we determined how p53 action influences
gene expression in HSCs. We crossed transgenic mice
harboring a tetracycline-response-element (TRE)-driven short-
hairpin RNA (shRNA) that efficiently represses p53 expression
(TG-p53.1224) to mice expressing rtTA (a reverse tetracycline-
controlled transactivator transgene) from the cytomegalovirus
promoter (Figure S4A) (Premsrirut et al., 2011). HSCs were
purified from an adult mouse by gradient centrifugation and
subjected to cell culture in the presence of doxycycline (Dox),
conditions in which p53 expression was suppressed (Fig-
ure S4B). This system enables p53 activity to be controlled in
HSCs simply by the addition and removal of Dox.
In the presence of Dox, activated HSCswere GFP positive and
were highly clonogenic. Upon Dox withdrawal, GFP expression
was rapidly reduced, and HSCs accumulated high levels of
p16, p21, and SA-b-gal (senescence-associated b-gal) activity
and eventually stopped proliferating with the characteristic
morphology of senescent cells (Figures 4A, 4B, and S4C).
Transcriptional profiling of proliferating versus senescent HSC
preparations (n = 3 per each condition) confirmed that both
sets of HSCs expressed high levels of the HSC markers aSMA
(Figure S4C), vimentin, and vinculin (data not shown). Gene set
enrichment analysis (GSEA) revealed significant similarities
between p53-arrested HSCs and the ‘‘KEGG_p53’’ pathway
gene set, as well as a previously identified senescence signature
(Figures S4C and S4D and Tables S1A and S1B) (Fridman and
Tainsky, 2008). Thus, Dox removal efficiently activated p53,
leading to senescence.
The transcriptional profiles were subject to gene ontology
(GO) analysis to systematically identify potential processes
affected by p53. Genes downregulated by p53 showed a signif-
icant enrichment for the GO term ‘‘cell cycle’’ (Figure 4D and
Table S1C) and included many E2F targets. Indeed, GSEA us-ing a list of established E2F target genes confirmed that these
are significantly underexpressed in senescent HSCs (Table
S1D). Alternatively, genes upregulated by p53 showed enrich-
ment for the GO terms ‘‘extracellular matrix,’’ ‘‘proteinaceous
extracellular matrix,’’ and ‘‘extracellular matrix structural con-
stituent’’ (Figure 4D and Table S1C). The ability of p53 to
repress cell cycle and ECM genes in senescent murine HSCs
is consistent with gene expression profiles from human HSCs
(Krizhanovsky et al., 2008) and its ability to limit a fibrogenic
response.
Genes upregulated in p53-expressing HSCs included biolog-
ical processes such as cell-cycle arrest, which have previously
been linked to p53 action and/or senescence (Figure 4D and
Table S1E). Interestingly, ‘‘Activation_of_immune_response’’
and ‘‘Activation_of_NF-kB_transcription_factor’’ gene sets
were enriched in senescent HSCs (Figure S4E and Table S1F).
This same analysis identified genes associated with ‘‘exocy-
tosis’’ and ‘‘Vesicle_mediated_transport’’ as overrepresented
in senescent HSCs (Figure S4E and Table S1F). All of these
observations suggest that p53 can directly or indirectly affect
protein secretion and modulate immune signaling (Krizhanovsky
et al., 2008).
To measure protein secretion, we subjected conditioned
media (CM) from p53-suppressed or p53-activated HSCs to a
murine antibody array that detects secreted cytokines and
chemokines (Figures 4E, 4F, and S4F). Senescent HSCs prefer-
entially secreted Il6, Icam1, and Ifng, whereas proliferating HSCs
secreted Il3, Il4, and Il5, among other factors, in agreement with
previously reported secretion profiles (Chien et al., 2011; Coppe´
et al., 2008; Crescenzi et al., 2011). The most notable changes
involved factors known to influence the differentiation and activ-
ity of macrophages (e.g., Il6, Ifng, and Il4 [Qian and Pollard,
2010]), a cell type known to modulate liver fibrosis (DuffieldCell 153, 449–460, April 11, 2013 ª2013 Elsevier Inc. 453
Figure 5. p53 Signaling through SASP
Modulates Macrophage Polarization and
Function
(A and B) Quantitative RT-PCR ofMsr1,Mrc1, and
Il1b expression in BMDMs (A) or KCs (B) exposed
to CM from proliferating (red) or senescent (blue)
HSCs. Data are relative to expression of BMDMs
with CM from senescent HSCs, normalized to the
average expression of the housekeeping genes
Hprt and Ubc. Values are mean + SD from three
independent experiments.
(C and D) BMDMs (C) and KCs (D) exhibited pref-
erential cytotoxic activity against senescent HSCs
(blue) when compared to proliferating HSCs (red).
Viable cell numbers are shown and are relative to
the number of viable cells without macrophages.
Values are mean + SD from two independent ex-
periments performed in triplicate.
(E) Sequence of movie frames displaying the tar-
geting of a senescent HSC (green cell; white arrow)
by BMDMs (red cells; red arrows).
(F and G) Cell viability in a coculture experiment:
premalignant cells were incubated with CM from
proliferating (red) or senescent (blue) HSCs and
were cocultured with (+) or without () BMDMs.
Two independent experiments were performed in
triplicate for two different cell lines (F andG). Viable
cell numbers are shown and are relative to the
number of viable cells cultured without BMDMs
and with normal media; values are mean + SD.
BMDM, bone-marrow-derived macrophages;
KCs, Kupffer cells; CM, conditioned media; Ren,
renilla; S, senescent; P, proliferating.
See also Figure S5 andMovies S1, S2, S3, and S4.et al., 2005). Of note, the preferential secretion of IL6 and IFNg
was confirmed in senescent human HSCs (Figures S4G
and S4H), highlighting the relevance of these findings to the
human setting.
p53 Signaling through SASP Influences Macrophage
Polarization
The data described above suggest that the SASP program
triggered by p53 might influence macrophage function and/or
polarization. Macrophages are myeloid cells that function in
innate immunity by phagocytizing cellular debris and patho-
gens and stimulating the adaptive immune response (Biswas
and Mantovani, 2010; Qian and Pollard, 2010). In cancer, these
subclasses can have different effects on tumorigenesis and
antitumor immunity. In general, ‘‘classically activated’’ M1
macrophages have natural roles in pathogen defense and
display antitumor activity, whereas ‘‘alternatively activated’’
M2 macrophages can promote angiogenesis and tissue re-
modeling, thereby supporting tumor progression and metas-
tasis. Ifng favors M1 polarization, whereas Il4 and Il13 trigger
M2 polarization. These macrophage subclasses can be distin-
guished by the differential expression of gene markers: M1
macrophages express higher levels of inflammatory and
antiangiogenic cytokines such as Il1b, whereas M2 macro-
phages express arginase-1 (Arg1), mannose receptor-1
(Mrc1), and macrophage scavenger receptor 1 (Msr1) (Mova-
hedi et al., 2010).454 Cell 153, 449–460, April 11, 2013 ª2013 Elsevier Inc.We next determined how factors secreted from proliferating
or senescent HSCs affected macrophage polarization. As
damaged livers are composed of resident (Kupffer cells, KCs)
and infiltrating macrophages (bone-marrow-derived macro-
phages, BMDMs), we studied the effects of HSCs on both
macrophage populations. Two genes associated with M2
phenotype, Mrc1 and Msr1, were upregulated in macrophages
incubated with CM from proliferating HSCs compared to
macrophages exposed to CM from senescent HSCs (Figures
5A, 5B, S5A, and S5B). Conversely, when macrophages were
exposed to CM from senescent HSCs, a significant increase
in the M1-marker Il1b was observed (Figures 5A and 5B).
Thus, p53 activation in HSCs shifts their secretory profile from
supporting M2 to M1 polarization. Such changes might be
important at different stages of the fibrogenic response but
have the net effect of promoting the tumor-inhibitory macro-
phage subtypes when p53 is intact.
p53-Activated M1-like Macrophages Eliminate
Senescent Cells
To evaluate the effects of p53 on ‘‘HSC-macrophage’’ interac-
tions, we cocultured either resident (KC) or infiltrating (BMDM)
macrophages with proliferating or senescent HSCs for 24–
48 hr and examined their proliferation and survival by cell quan-
tification and time-lapse video microscopy. Although the pres-
ence of macrophages (BMDMs and KCs) had little effect on
the accumulation of proliferating HSCs, they showed a marked
Figure 6. NF-kB Mediates p53-Dependent
SASP
(A) GSEA plots evaluating p53-dependent
changes in NF-kB signaling pathway.
(B) Immunostaining of proliferating (+Dox)
and senescent HSCs (Dox) with anti-p65
antibody (top) and counterstained with DAPI
(bottom) to show nuclear NF-kB accumulation
and SAHF formation, respectively, in senescent
HSCs.
(C) Murine cytokine array for conditioned media
from senescent HSCs transduced with Renilla or
p65 shRNA. Bars represent the average of two
independent experiments (log2). Factors upregu-
lated in senescent HSCs (Figure 4E) are indicated
in orange.
(D) Top, cytokine array blot extract showing
secreted Icam1 in cells transduced with Renilla
or p65 shRNA, in proliferating or senescent
HSCs. Bottom, p65 and Icam1 protein levels
in the same cells. b-actin serves as loading
control.
(E and F) Cytotoxicity of senescent HSCs
(blue) infected with shRNAs (Renilla and p65
in E; Renilla, Il6, Ifng, and Icam1 in F) and
incubated with (+) or without () BMDMs. The
cytotoxicity (dark blue) is relative to the basal
cytotoxicity (light blue, in the absence of incubation with BMDMs, which has been normalized to 1). Values are mean + SD from triplicates.
ES; enrichment score; NES, normalized enrichment score; Ren, renilla; BMDM, bone-marrow-derived macrophages.
See also Figures S4 and S6 and Table S1.ability to eliminate senescent HSCs (Figures 5C–5E and Movies
S1, S2, S3, and S4). Similarly, BMDM were more effective at
targeting primary p53+/+ HSCs, which senesce in culture, than
their p53/ counterparts, confirming that p53-mediated senes-
cence stimulates HSC elimination by macrophages (Figures
S5C–S5E). Additionally, natural killer (NK) cells preferentially
target senescent human (Chien et al., 2011; Krizhanovsky
et al., 2008) andmurine HSCs (Figure S5F), implying that p53 ac-
tion in senescent cells triggers altered surveillance by multiple
immune cell types.
If p53 action in HSCs contributes to an antitumor microenvi-
ronment through its impact on macrophage polarization, we
hypothesized that ‘‘HSC-macrophage’’ interactions might alter
the proliferation or survival of premalignant cells. To test this,
we exploited two premalignant hepatoblast progenitor lines pre-
viously used in our laboratory to identify new tumor suppressor
genes in HCC (Zender et al., 2008). These cells were cocultured
with BMDMs, incubated with CM from either growing or senes-
cent HSCs, and quantified 48 hr later. The combination of
BMDMs with CM from proliferating HSCs enhanced proliferation
of premalignant cells when compared to BMDMs with CM from
senescent HSCs or BMDMs with control media (Figures 5F
and 5G). This outcome could not be explained by the individual
or the additive effects of CM from proliferating HSCs or BMDMs
alone on premalignant cell proliferation but rather is explained
by the significant interaction between both parameters
(interaction p value: p = 0.0470 [Figure 5F] and p = 0.0027 [Fig-
ure 5G]). Hence, in this assay, p53 action and senescence in
HSCs reduces their ability to stimulate a proproliferative
microenvironment.p53 and NF-kB Cooperate to Induce SASP and Influence
Macrophage Function
To further understand how p53 influences the tissue microenvi-
ronment, we studied the regulation of SASP genes in HSCs.
Whereas some of these genes are direct p53 targets (e.g.,
Icam1), others have not been directly linked to p53. We and
others have identified a crucial role for NF-kB in the control of
SASP and have shown that p53 cooperates with NF-kB to trigger
senescence (Acosta et al., 2008; Chien et al., 2011; Jing et al.,
2011). Accordingly, several factors selectively secreted by
senescent cells—Il6, Icam1, and Ifng—are known NF-kB targets
(Chien et al., 2011; Crescenzi et al., 2011), and GSEA confirmed
that NF-kB signaling was highly upregulated in senescent HSCs
(Figure 6A). As has been observed in other contexts (Ryan et al.,
2000), p53 triggered NF-kB activation as assessed by the
nuclear accumulation of the NF-kB subunit p65 (Figures 6B
and S6A). How this occurs in HSCs remains to be determined,
though we note that several genes upregulated in senescent
HSCs (e.g., Eda2r or Pycard) are known NF-kB activators
and either established p53 targets (Ohtsuka et al., 2004; Tani-
kawa et al., 2009) or (e.g., Tnf, Camk2a, Card11, and Ikbkb)
harbored consensus p53-binding motifs (Figures S6B and S6C
and Table S1G).
To further explore the role of NF-kB in controlling SASP, we
determined how suppression of the essential NF-kB component
p65RelA affected expression of SASP factors and the targeting of
senescent HSCs by BMDMs. shRNAs targeting p65 were cloned
into the retroviral vector LMN (Figure S6D), and a Renilla
luciferase shRNA was used as a neutral control. Upon p53
activation, cells expressing p65 shRNAs showed reducedCell 153, 449–460, April 11, 2013 ª2013 Elsevier Inc. 455
Figure 7. p53 Activity in HSCs Promotes an
Antitumor Microenvironment
(A) Quantification of viable Cd45+Cd11b+Gr1
cells in CCl4-treated mice (n = 3 from each geno-
type). Values are mean + SD.
(B and C) Quantitative RT-PCR of FACS-sorted
Cd45+Cd11b+Gr1 cells for Il1b (B) and Mrc1 (C)
expression. The results are normalized to the
average expression of the housekeeping genes
Hprt and Ubc and are relative to the expression in
HSC-p53D/D mice. Values are mean + SD of three
independent livers per genotype.
(D–H) Staining for Cd11b (red) and Il1b (green) (D)
and Iba1 (red) and Mrc1 (green) (E), revealing less
Cd11b+ or Iba1+ macrophages, less Cd11b+Il1b+
macrophages, and more Iba1+Mrc1+ macro-
phages in HSC-p53D/D CCl4-treated livers than
in control livers. Quantification of Cd11b+ cells (%
of total DAPI+ cells) (F), Cd11b+Il1b+ cells (% of
total Cd11b+ cells) (G), and Mrc1+Iba1+ cells (% of
total Iba+ cells) (H). Scale bars, 100 mm. Yellow
arrows indicate double-stained cells. Values are
mean + SD.
See also Figure S7.expression and secretion of Icam1 and Il6 (Figures 6C, 6D, and
S6E) compared to cells expressing the control shRNA. p65 sup-
pression also reduced the abundance of IfngmRNA, though the
effect of this treatment on Ifng secretion was modest (Figures
6C, 6D, and S6E). Accordingly, p65 knockdown had no effect
on the viability of proliferating HSCs that were cocultured with
BMDMs (data not shown) but rescued the cytotoxic effect of
BMDMs on senescent HSCs (Figure 6E). Similar results were ob-
tained when using shRNAs against the NF-kB targets Il6, Icam1,
or Ifng (Figures 6F and S6F), indicating that the ability of macro-
phages to target senescent HSCs is a direct SASP effect and not
merely a consequence of cell-cycle arrest. These results support
the antitumorigenic role of NF-kB in senescent cells (Chien et al.,
2011; Jing et al., 2011) and highlight the cooperation between
NF-kB and p53 in executing the senescence program.
p53 Activity in HSCs Promotes an Antitumor
Microenvironment
The ability of p53 to influence macrophage polarization raised
the possibility that p53 status in HSCs might influence the
composition of macrophage subpopulations in damaged livers.
To examine this, we used fluorescence-activated cell sorting456 Cell 153, 449–460, April 11, 2013 ª2013 Elsevier Inc.(FACS) to quantify, isolate, and charac-
terize CD45+Cd11b+Gr1 macrophages
from CCl4-treated livers. Surprisingly, to-
tal macrophage populations were signifi-
cantly decreased in HSC-p53D/D livers
when compared to GFAP-Cre and p53-
loxP controls (Figures 7A and S7A; p =
0.002 and p = 0.002, respectively). Using
a quantitative RT-PCR assay of macro-
phage polarization markers to assess
the relative abundance of macrophage
subtypes in these sorted populations,we observed that those macrophages present in the control
GFAP-Cre and p53-loxP livers showed higher expression levels
of the M1-marker Il1b (Figure 7B; p = 0.001 and p = 0.043,
respectively), whereas HSC-p53D/D livers were enriched for the
M2-marker Mrc1 (Figure 7C; p = 0.012 and p = 0.048,
respectively).
These results were confirmed by directly analyzing liver sec-
tions using immunofluorescence with antibodies recognizing
different macrophage subpopulations (Figures 7D, 7E, S7B,
and S7C). The percentage of cells expressing the general macro-
phagemarkers Cd11b or Iba1 was reduced inHSC-p53D/D livers
(Figure 7F; p = 0.004 and p = 0.027 relative to GFAP-Cre and
p53-LoxP, respectively). More than 50% of Cd11b+ macro-
phages in the GFAP-Cre and p53-LoxP mice were also positive
for the M1-marker Il1b, whereas only 25% of macrophages pre-
sent inHSC-p53D/D livers were Il1b positive (Figures 7D, 7G, and
S7B; p = 0.017 and p = 0.014, respectively). By contrast, more
than 35% of the macrophages present in HSC-p53D/D livers ex-
pressed the M2-marker Mrc1, compared to only 5%–15% of
these cells in GFAP-Cre and p53-LoxP livers (Figures 7E, 7H,
and S7C; p = 0.0423 and p = 0.0012 when compared to
GFAP-Cre and p53-LoxP, respectively). Still, not all macrophage
populations could be identified using these markers, suggesting
that yet other macrophage subclasses might be present in
damaged livers (Ramachandran et al., 2012). Regardless, p53
action in HSCs can trigger a quantitative and qualitative enrich-
ment of antitumor M1 macrophages in damaged livers, which
could, in part, explain the non-cell-autonomous tumor-suppres-
sive effects of p53.
DISCUSSION
The mechanisms that link chronic inflammatory responses to
tumorigenesis remain a subject of intense investigation, under-
scoring the need to better understand complex functional inter-
actions that occur between different cell types in tissues.
Following chemical injury to the liver, quiescent HSCs, which
are of mesenchymal origin, enter the cell cycle, differentiate,
and sustain a chronic inflammatory response accompanied by
fibrosis (Zhang and Friedman, 2012). In the face of continued
stress, a cycle of persistent injury, hepatocyte death, and further
HSC expansion can induce cirrhosis and generate a microenvi-
ronmental milieu that provides fertile ground for HCC formation.
Although proliferating HSCs initially contribute to the inflamma-
tory response, their eventual p53-dependent senescence re-
strains fibrosis, organ failure, and hepatic tumorigenesis.
Aberrant activation of Cre in hepatocytes cannot explain the
increased propensity of HSC-p53D/D mice to epithelial tumor
development because the HCCs arising in Cre-expressing
mice showed no evidence of recombination at the p53 locus.
Although Cre-activatable lacZ reporter expression was detected
in fibrotic areas of livers derived from tumor-bearing mice, none
of the epithelial tumors were LacZ positive. Hence, p53 can act
to suppress tissue damage and ultimately tumorigenesis in a
non-cell-autonomous manner. These results are consistent
with the observation that MCF7 breast cancer cells produce
more tumors when injected subcutaneously into p53 null mice
compared to wild-type controls (Kiaris et al., 2005) and are remi-
niscent of studies supporting a non-cell-autonomous role for
Pten in suppressing breast cancer development in transgenic
mice (Trimboli et al., 2009).
Nonetheless, the Cre transgene alone may impact tumorigen-
esis in different ways. Hence, in some experiments, we noted dif-
ferences in the behavior of our GFAP-Cre and p53-LoxP control
strains (e.g., see Figures 1C, 1D, and 7A–7C). This effect was
most notable in male mice, which are substantially more tumor
prone than females (Naugler et al., 2007), and GFAP-Cre mice
showed a significant decrease in tumors compared to p53-
loxP animals, confounding comparisons between tumors in
this gender (data not shown). Though the basis for the male
bias remains unclear, we suspect that some form of Cre-medi-
ated damage impacts the proliferation of HSCs as has been
seen in some other settings (Forni et al., 2006). Mice harboring
Cre transgenes capable of transient Cre expression (e.g., Cre-
ER) might substantially reduce this effect and improve the
robustness of the model.
Although p53 activity in HSCs can suppress HCC, it remains
unclear whether or not mutational disruption of this program is
relevant during the natural HCC progression. In principle, the
high rate of cell turnover in damaged livers could lead to the se-lection of p53 mutant HSCs, though currently there is no indica-
tion that p53 mutations are present in cells associated with the
fibrotic lesions adjacent to liver tumors. However, in other con-
texts, p53 mutations have been observed in stromal cells in
bothmice and humans (Hill et al., 2005; Kurose et al., 2002), sug-
gesting that such a possibility cannot be excluded. Regardless,
the fact that a non-cell-autonomous stromal program can sup-
press organ damage and epithelial cell transformation provides
a new avenue for exploiting knowledge of the p53 network in
controlling ‘‘fibrosis-cirrhosis-carcinoma’’ progression.
Our data imply that p53 acts non-cell autonomously to pro-
mote an antitumorigenic tissue microenvironment. Engagement
of p53 in activated murine HSCs triggers an antiproliferative pro-
gram that manifests the features of senescence observed in
other cell types; these features include global changes in the
expression of cell-cycle regulators, SASP, and production of
immune modulators that were previously linked to fibrosis reso-
lution (Krizhanovsky et al., 2008). Of note, whereas others re-
ported a general suppression of the secretory phenotype by
p53 in senescent fibroblasts (Coppe´ et al., 2008), we observed
decisively qualitative effects in HSCs, which included a signifi-
cant switch in the cytokines produced by senescent versus
proliferating cells.
The most prominent effects observed involved factors that in-
fluence macrophage biology. Indeed, the senescent state trig-
gered by p53 caused a significant increase in the secretion of
factors known to promote M1 polarization, which is character-
ized by Il1b expression and an increased propensity for cell
killing and phagocytosis (Biswas and Mantovani, 2010). By
marked contrast, p53 suppressed the secretion of factors
associated with M2 polarization. Accordingly, CM from p53-ex-
pressing HSCs promoted M1 polarization of macrophages,
which then acquired the ability to target senescent HSCs.
Conversely, CM from proliferating HSCs with suppressed p53
activity stimulated M2 polarization of macrophages, which
were unable to target HSCs but could stimulate the proliferation
of premalignant hepatoblasts.
The action of p53 in stimulating an antitumor microenviron-
ment is likely to involve both direct and indirect mechanisms.
On one hand, several immune-modulatory factors upregulated
in HSCs undergoing senescence are direct p53 transcriptional
targets. However, p53 also has a complex but well-established
role in coordinating gene expression together with NF-kB, an
immunemodulating transcription factor. The impact of this inter-
section is context dependent, with some studies suggesting that
NF-kB can antagonize p53 function, whereas others imply that it
can complement certain p53 effects. During senescence, p53
and NF-kB cooperate in the execution of the program (Chien
et al., 2011; Jing et al., 2011), and, as shown here, this interplay
influences macrophage polarization and the subsequent target-
ing of senescent cells. Precisely how this occurs remains to be
determined and likely involves a direct effect of p53 on the
transcription of NF-kB-activating factors as well as unidentified
indirect effects.
Beyond its effects on macrophages, p53 signaling likely influ-
ences the microenvironment in additional ways. For example,
cells triggered to senesce by p53 can recruit NK cells and cyto-
toxic T lymphocytes into inflammatory sites enhancing immuneCell 153, 449–460, April 11, 2013 ª2013 Elsevier Inc. 457
surveillance and can limit the production of new blood vessels
through the induction of antiangiogenic molecules (Dameron
et al., 1994; Kang et al., 2011; Krizhanovsky et al., 2008). In pro-
moting these processes, p53 acts in a quantitative way to
augment recruitment of immune cells or tumor inhibitory factors.
By contrast, the effects of p53-driven SASP on macrophage
polarization are unique in that they qualitatively alter macro-
phage function, an effect that can be observed in damaged livers
in vivo.
Our studies support a model whereby normal p53 activity in
HSCs acts to limit the extent of liver damage and to helpmaintain
organ integrity through its impact on SASP. Among the many
factors that contribute to this effect, macrophages have long
been considered to be crucial for the formation of the fibrotic
scar and, paradoxically, for the resolution of fibrosis (Duffield
et al., 2005; Ramachandran et al., 2012). An intriguing possibility
is that the differential effect of proliferating and senescent HSCs
on macrophage polarization underlies their opposing role in
liver damage responses. In this scenario, liver damage activates
HSC proliferation, which promotes the recruitment and M2 po-
larization of macrophages that stimulate fibrosis as part of the
tissue-remodeling and proangiogenic response that maintains
organ integrity. Subsequently, p53 activation and senescence
in HSCs could favor M1 polarization of macrophages that coun-
teracts these effects by promoting an antifibrogenic environment
and elimination of accumulated HSCs. In the presence of chronic
liver damage, proliferating HSCs that fail to activate p53 would
continue to accumulate, biasing macrophage populations in
the liver to the tumorigenic M2 subtype that can also enhance
the proliferation of premalignant cells. Consistent with this
view, M2 macrophages accumulate in patients with chronic liver
disease (Zimmermann et al., 2011), whereas the accumulation of
M1 macrophages has been linked to reduced fibrosis (Hesse
et al., 2000).
We propose that the non-cell-autonomous action of p53 in
HCC is an inadvertent consequence of its action in this natural
wound healing response. Thus, the same factors that influence
wound resolution create a microenvironment that resists epithe-
lial cell transformation through a variety of mechanisms
including, as shown here, an increase in production of antitumor
modulators and cell types. However, upon chronic damage, an
inherently protumorigenic milieu created by M2 macrophages
and by other factors affected by proliferating HSCs predomi-
nates and creates an environment prone to epithelial cell trans-
formation. Although further studies are needed, the fact that
p53 can communicate a tumor-suppressive program through
soluble components that modify the tissue microenvironment
offers insights into this well-characterized tumor-suppressor
network and provides optimism that these effects might eventu-
ally be phenocopied therapeutically for improving liver function
and reducing liver cancer incidence.EXPERIMENTAL PROCEDURES
Animals and Housing
Animal work was conducted in accordance with protocols approved by the
Institutional Animal Care and Use Committees at CSHL and MSKCC. Mice
were maintained under specific pathogen-free conditions, and food and water458 Cell 153, 449–460, April 11, 2013 ª2013 Elsevier Inc.were provided ad libitum. Animal treatment details are in Extended Experi-
mental Procedures.
Histological Analysis
Paraffin-embedded tissue sections were stained with H&E for routine
examination, Sirius red for visualization of fibrotic deposition, and Gordon
and Sweet’s for Reticulin. At least three whole sections from each animal
were scanned with Laser Scanner Cytometry (CompuCyte; Aperio) for
fibrosis analysis. The images were quantified using NIH ImageJ software
(http://rsb.info.nih.gov/ij/). The amount of fibrotic tissue was calculated rela-
tive to the total analyzed liver area. Detection of transgenic-b-gal activity
was performed as previously described at pH = 7.4 (Krizhanovsky et al.,
2008).
Tissue Culture
HSCs were grown in DMEM supplemented with 10% FBS, 1% glutamine,
100 U/ml penicillin, 100 mg/ml streptomycin, and 1 mg/ml doxycycline (Dox).
Senescence was induced by withdrawing Dox, replicative exhaustion, or by
adding etoposide (100 mM, Sigma). Detection of senescence-associated
b-gal activity was performed as previously described at pH = 5.5 (Krizhanov-
sky et al., 2008). Cell isolation and cytotoxicity experiments are described in
Extended Experimental Procedures.
Quantitative RT-PCR and Expression Array Analysis
Murine HSCs, primary BMDMs, or sorted macrophages were freshly
homogenized in Trizol (GIBCO). RNA isolation, cDNA synthesis, and quantita-
tive RT-PCRs were performed as previously described (Xue et al., 2007).
Microarray experiments were performed on Mouse Genome 430A 2.0 Arrays
(Affymetrix) at MSKCC Genomics Core. GSEA analysis was performed using
GSEA v2.07 software with 1,000 phenotype permutations. For GO term anal-
ysis, DAVID Bioinformatics Resources 6.7 was utilized at http://david.abcc.
ncifcrf.gov/home.jsp. Gene sets used in this study, technical details, and the
list of Taqman probes are included in Table S1 and Extended Experimental
Procedures.
Immunoblotting
Liver tissues were lysed in Laemmli buffer using a tissue homogenizer. Cellular
lysates fromHSCs ormacrophageswere also prepared by lysing with Laemmli
buffer. Equal amounts of protein were separated on 12%SDS-polyacrylamide
gels and transferred to PVDF membranes. The abundance of b-actin was
monitored to ensure equal loading. Images were analyzed using the NIH Image
J software. Immunofluorescence staining was performed as previously
described (Chien et al., 2011). Alexa Fluor conjugates (Molecular Probes)
were used as the secondary antibodies, and DNA was visualized with 49-6-
diamidino-2-phenylindole (DAPI; Vector Laboratories). The details of fluores-
cence quantification and the list of antibodies can be found in Extended
Experimental Procedures.
Sorting of Macrophages
Livers fromCCl4-treated animals were digested with dispase (0.2%, GIBCO) in
HBSS during 30 min at 37C and then filtered through a 100 mm mesh filter.
Red blood cells were eliminated by washing with 13 RBC Lysis Buffer
(eBioscience). Samples were then washed with FACS buffer (1% BSA in
PBS), followed by Fc block for 15 min at 4C and antibody labeling for
15 min at 4C. Antibodies used for cell type identification were CD45-APC
(1:500; BD Biosciences PharMingen), Gr1-FITC (1:500; BD Biosciences
PharMingen), and Cd11b-PE (1:500; BD Biosciences PharMingen). FACS
buffer with DAPI (Invitrogen) was then added to each sample, followed by
acquisition and sorting on an Aria1 sorter (BD).
Statistics
Statistical significance was calculated by two-tailed Student’s t test. Log rank
test was used to determine overall and pairwise significance for survival
curves. Interaction between CM and BMDM effects was calculated with
two-way ANOVA. Prism 5 Software was used for the generation of the survival
graphs and statistical analyses. Significance values are *p < 0.05, **p < 0.01,
and ***p < 0.001. Ns stands for nonsignificant (p > 0.05).
ACCESSION NUMBERS
All raw microarray data files are available in the GEO database (GSE39469).
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Supplemental Information includes Extended Experimental Procedures, seven
figures, one table, and four movies and can be found with this article online at
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